Qingzhou Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qingzhou Kong has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Yueyue Li
Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, China
10 shared publications - Xiuli Zuo
Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China
6 shared publications - Yanqing Li
Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, China
6 shared publications Miao Duan
4 shared publicationsXiuli Zuo
3 shared publicationsHongyu Zhao
2 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (7) , e70290
Immediate Versus On‐Demand Direct Endoscopic Necrosectomy for Necrotizing Pancreatitis: A Systematic Review and Meta‐Analysis
Background: The optimal timing of direct endoscopic necrosectomy (DEN) for Necrotizing Pancreatitis (NP) remains unclear. This meta‐analysis aimed to evaluate the efficacy and safety of immediate DEN compared with on‐demand DEN. Methods: PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched to identify studies. The primary outcome measure was clinical success. Results: Seven studies (4 RCTs and 3 observational studies) comprising 616 patients were included. Immediate DEN did not demonstrate a statistically significant advantage in clinical success (OR: 1.92, 95% CI 1.01–3.63). No significant differences were found in technical success (OR: 1.62, 95% CI: 0.43–6.09), total number of DEN (standardized mean difference: 0.31, 95% CI: −0.21–0.84), need for additional percutaneous drainage (OR: 0.53, 95% CI: 0.27–1.03), need for salvage surgery (OR: 0.60, 95% CI: 0.28–1.27), procedure‐related adverse events were comparable between groups (OR: 0.81, 95% CI: 0.51–1.28), disease‐related adverse events (OR: 0.84, 95% CI: 0.34–2.13), mortality (OR: 1.11, 95% CI: 0.47–2.59). In RCT‐only analyses, these findings remained consistent. Immediate DEN lowered stent migration risk (OR: 0.31, 95% CI: 0.11–0.92), but lost significance in RCT‐only analysis. Conclusion: This meta‐analysis found no overall superiority of immediate DEN over on‐demand DEN for patients with NP, highlighting the need to identify specific subgroups that benefit from an upfront necrosectomy strategy.
- 31 August 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (7) , e70290
Open AccessImmediate Versus On‐Demand Direct Endoscopic Necrosectomy for Necrotizing Pancreatitis: A Systematic Review and Meta‐Analysis
Background: The optimal timing of direct endoscopic necrosectomy (DEN) for Necrotizing Pancreatitis (NP) remains unclear. This meta‐analysis aimed to evaluate the efficacy and safety of immediate DEN compared with on‐demand DEN. Methods: PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched to identify studies. The primary outcome measure was clinical success. Results: Seven studies (4 RCTs and 3 observational studies) comprising 616 patients were included. Immediate DEN did not demonstrate a statistically significant advantage in clinical success (OR: 1.92, 95% CI 1.01–3.63). No significant differences were found in technical success (OR: 1.62, 95% CI: 0.43–6.09), total number of DEN (standardized mean difference: 0.31, 95% CI: −0.21–0.84), need for additional percutaneous drainage (OR: 0.53, 95% CI: 0.27–1.03), need for salvage surgery (OR: 0.60, 95% CI: 0.28–1.27), procedure‐related adverse events were comparable between groups (OR: 0.81, 95% CI: 0.51–1.28), disease‐related adverse events (OR: 0.84, 95% CI: 0.34–2.13), mortality (OR: 1.11, 95% CI: 0.47–2.59). In RCT‐only analyses, these findings remained consistent. Immediate DEN lowered stent migration risk (OR: 0.31, 95% CI: 0.11–0.92), but lost significance in RCT‐only analysis. Conclusion: This meta‐analysis found no overall superiority of immediate DEN over on‐demand DEN for patients with NP, highlighting the need to identify specific subgroups that benefit from an upfront necrosectomy strategy.
- 1 May 2026
- Published by Wiley in Journal of Digestive Diseases
- Vol. 27 (5-6) , 205-213
Quality of Helicobacter pylori Infection Management Through Telemedicine: A Nationwide Cross‐Sectional Study
Objective: To evaluate the clinical practice and quality of first‐line Helicobacter pylori eradication therapy by gastroenterologists in direct‐to‐consumer telemedicine (DTCT) settings. Methods: The study was conducted between November 2024 and February 2025 using unannounced standardized patients (USPs). Six trained and validated USPs questioned clinicians using specific H. pylori infection scenarios on hospital‐ or enterprise‐sponsored DTCT platforms. Accessibility and effective consultation rates of the enquiry platforms were evaluated. The consultation process at each visit was also analyzed for guideline adherence and patient‐centeredness. Results: USPs conducted 552 visits on 53 hospital‐ and 19 enterprise‐sponsored accessible platforms, with effective consultation rate of 65.6% (362 of 552). Based on a 10‐point quality checklist, the overall guideline adherence score was 5.0, which was significantly higher for the enterprise‐sponsored platforms than for hospital platforms (5.4 ± 2.7 vs. 4.8 ± 2.8, p = 0.045). When stratified by professional title of the clinicians involved, clinicians with intermediate title achieved a higher guideline adherence score than those with junior or senior titles (5.5 ± 2.7 vs. 4.3 ± 2.7 vs. 4.8 ± 2.8, p = 0.009). Altogether 72% of clinicians prescribed the correct treatment regimen for H. pylori infection. Furthermore, patient satisfaction during the treatment process was generally acceptable. Conclusions: We identified gaps in guideline adherence and clinical standardization for telemedicine‐based H. pylori eradication in China. Further nationwide standardized training for gastroenterologists should prioritize structured history‐taking, appropriate prescribing, resistance‐guided antibiotic selection, and patient follow‐up management. Trial Registration: ClinicalTrials.gov ID: NCT06749873
- 1 May 2026
- Published by Wiley in Journal of Digestive Diseases
- Vol. 27 (5-6) , 205-213
Quality of Helicobacter pylori Infection Management Through Telemedicine: A Nationwide Cross‐Sectional Study
Objective: To evaluate the clinical practice and quality of first‐line Helicobacter pylori eradication therapy by gastroenterologists in direct‐to‐consumer telemedicine (DTCT) settings. Methods: The study was conducted between November 2024 and February 2025 using unannounced standardized patients (USPs). Six trained and validated USPs questioned clinicians using specific H. pylori infection scenarios on hospital‐ or enterprise‐sponsored DTCT platforms. Accessibility and effective consultation rates of the enquiry platforms were evaluated. The consultation process at each visit was also analyzed for guideline adherence and patient‐centeredness. Results: USPs conducted 552 visits on 53 hospital‐ and 19 enterprise‐sponsored accessible platforms, with effective consultation rate of 65.6% (362 of 552). Based on a 10‐point quality checklist, the overall guideline adherence score was 5.0, which was significantly higher for the enterprise‐sponsored platforms than for hospital platforms (5.4 ± 2.7 vs. 4.8 ± 2.8, p = 0.045). When stratified by professional title of the clinicians involved, clinicians with intermediate title achieved a higher guideline adherence score than those with junior or senior titles (5.5 ± 2.7 vs. 4.3 ± 2.7 vs. 4.8 ± 2.8, p = 0.009). Altogether 72% of clinicians prescribed the correct treatment regimen for H. pylori infection. Furthermore, patient satisfaction during the treatment process was generally acceptable. Conclusions: We identified gaps in guideline adherence and clinical standardization for telemedicine‐based H. pylori eradication in China. Further nationwide standardized training for gastroenterologists should prioritize structured history‐taking, appropriate prescribing, resistance‐guided antibiotic selection, and patient follow‐up management. Trial Registration: ClinicalTrials.gov ID: NCT06749873
- Open Access
- 14 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (10) , e18522
AI‐Based D‐Amino Acid Substitution for Optimizing Antimicrobial Peptides to Treat Multidrug‐Resistant Bacterial Infection
D‐amino acid substitution provides an effective strategy for optimizing antimicrobial peptides (AMPs) by enhancing their stability. However, the absence of universal rules renders traditional screening methods time‐consuming and labor‐intensive, potentially leading to reduced or complete loss of activity. Here, we curated a D‐amino acid‐substituted AMP dataset from published literature and databases. We then developed ADAPT, an AI‐based tool for predicting the functional impact of D‐amino acid substitutions, and integrated it into a high‐throughput screening pipeline for AMP optimization. Of the variants obtained through this pipeline, 80% exhibited enhanced antibacterial activity. Among these, dR2‐1 showed exceptional broad‐spectrum antimicrobial activity, reduced toxicity, and substantially improved stability. Mechanistic studies confirmed a membrane‐targeting antibacterial mode of action. Furthermore, we engineered a hydrogel delivery system that effectively treated cutaneous infections in mice. Overall, our study established an AI‐based framework for D‐amino acid substitution in AMPs, enabling the efficient discovery of potent and stable candidates with enhanced clinical translation potential.
- 14 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (10) , e18522
Open AccessAI‐Based D‐Amino Acid Substitution for Optimizing Antimicrobial Peptides to Treat Multidrug‐Resistant Bacterial Infection
D‐amino acid substitution provides an effective strategy for optimizing antimicrobial peptides (AMPs) by enhancing their stability. However, the absence of universal rules renders traditional screening methods time‐consuming and labor‐intensive, potentially leading to reduced or complete loss of activity. Here, we curated a D‐amino acid‐substituted AMP dataset from published literature and databases. We then developed ADAPT, an AI‐based tool for predicting the functional impact of D‐amino acid substitutions, and integrated it into a high‐throughput screening pipeline for AMP optimization. Of the variants obtained through this pipeline, 80% exhibited enhanced antibacterial activity. Among these, dR2‐1 showed exceptional broad‐spectrum antimicrobial activity, reduced toxicity, and substantially improved stability. Mechanistic studies confirmed a membrane‐targeting antibacterial mode of action. Furthermore, we engineered a hydrogel delivery system that effectively treated cutaneous infections in mice. Overall, our study established an AI‐based framework for D‐amino acid substitution in AMPs, enabling the efficient discovery of potent and stable candidates with enhanced clinical translation potential.
- 1 November 2025
- Published by Wiley in Helicobacter
- Vol. 30 (6) , e70101
Antibiotic Combinations in Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Network Meta‐Analysis
Background and Aims: The rising antibiotic resistance of Helicobacter pylori has led to variability in efficacy of bismuth‐containing quadruple therapy (BcQT). This network meta‐analysis (NMA) aimed to compare the efficacy of antibiotic combinations in first‐line BcQT. Methods: Following PRISMA guidelines with PROSPERO registration (CRD420251005598), we systematically searched PubMed, Embase, Web of Science, and Cochrane Library for randomized controlled trials (RCTs) published between January 1, 2005 and March 21, 2025. Eligible studies were selected by predefined criteria. Dichotomous outcomes included H. pylori eradication rates, adverse events, and compliance, analyzed as odds ratios (ORs) with 95% credible intervals (95% CrI) or 95% confidence intervals (95% CI). Treatments were ranked via surface under the cumulative ranking curve (SUCRA). Results: This NMA included 25 RCTs ( n = 7624) evaluating 19 regimens. Amoxicillin‐metronidazole ranked highest globally (SUCRA = 0.866) in intention‐to‐treat analyses and in Asia (SUCRA = 0.851), particularly during 2016–2025 (SUCRA = 0.859; OR = 3.43, 95% CrI 1.17–10.05). Metronidazole‐tetracycline was optimal in Europe (SUCRA = 0.969; OR = 2.13, 95% CrI 1.15–3.95), amoxicillin‐minocycline in China (SUCRA = 0.733). Notably, regimens including levofloxacin or clarithromycin significantly decreased eradication rates in China (OR = 1.32; 95% CI 1.04–1.66; p = 0.02). Amoxicillin‐furazolidone had the poorest adverse events (SUCRA = 0.792). Compliance was highest with amoxicillin‐moxifloxacin (SUCRA = 0.878). Conclusion: Superior eradication was achieved with BcQT by utilizing dual low‐resistance antibiotics per local surveillance data. Amoxicillin‐metronidazole may represent optimal regimens for primary H. pylori eradication efficacy in BcQT. Substantial efficacy variation in antibiotic combinations necessitates tailored treatment guided by antibiotic resistance surveillance.
- 1 November 2025
- Published by Wiley in Helicobacter
- Vol. 30 (6) , e70101
Antibiotic Combinations in Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Network Meta‐Analysis
Background and Aims: The rising antibiotic resistance of Helicobacter pylori has led to variability in efficacy of bismuth‐containing quadruple therapy (BcQT). This network meta‐analysis (NMA) aimed to compare the efficacy of antibiotic combinations in first‐line BcQT. Methods: Following PRISMA guidelines with PROSPERO registration (CRD420251005598), we systematically searched PubMed, Embase, Web of Science, and Cochrane Library for randomized controlled trials (RCTs) published between January 1, 2005 and March 21, 2025. Eligible studies were selected by predefined criteria. Dichotomous outcomes included H. pylori eradication rates, adverse events, and compliance, analyzed as odds ratios (ORs) with 95% credible intervals (95% CrI) or 95% confidence intervals (95% CI). Treatments were ranked via surface under the cumulative ranking curve (SUCRA). Results: This NMA included 25 RCTs ( n = 7624) evaluating 19 regimens. Amoxicillin‐metronidazole ranked highest globally (SUCRA = 0.866) in intention‐to‐treat analyses and in Asia (SUCRA = 0.851), particularly during 2016–2025 (SUCRA = 0.859; OR = 3.43, 95% CrI 1.17–10.05). Metronidazole‐tetracycline was optimal in Europe (SUCRA = 0.969; OR = 2.13, 95% CrI 1.15–3.95), amoxicillin‐minocycline in China (SUCRA = 0.733). Notably, regimens including levofloxacin or clarithromycin significantly decreased eradication rates in China (OR = 1.32; 95% CI 1.04–1.66; p = 0.02). Amoxicillin‐furazolidone had the poorest adverse events (SUCRA = 0.792). Compliance was highest with amoxicillin‐moxifloxacin (SUCRA = 0.878). Conclusion: Superior eradication was achieved with BcQT by utilizing dual low‐resistance antibiotics per local surveillance data. Amoxicillin‐metronidazole may represent optimal regimens for primary H. pylori eradication efficacy in BcQT. Substantial efficacy variation in antibiotic combinations necessitates tailored treatment guided by antibiotic resistance surveillance.
- 27 October 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (2) , e12
Letter to the Editor
- 27 October 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (2) , e12
Letter to the Editor
- 1 September 2024
- Published by Wiley in Helicobacter
- Vol. 29 (5) , e13144
Optimal Duration of Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis
Background: The eradication of Helicobacter pylori (H. pylori) is crucial due to its rising prevalence and increasing resistance. Bismuth‐containing quadruple therapies (BcQTs) have been proposed as a viable treatment option; however, the optimal duration for it remains contentious. This systematic review and meta‐analysis aimed to compare the clinical efficacy of short‐term BcQT (defined as 7 or 10 days) with a standard 14‐day course.Methods: A systematic search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted for randomized controlled trials published in English until June 20, 2024. Eligibility criteria were applied to identify relevant studies. Summary risk ratios (RRs) and 95% confidence intervals (CIs) were calculated for the included studies regarding eradication rates, adverse effects, and compliance. This systematic review and meta‐analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement and was previously registered in PROSPERO under registration number CRD42024547773.Results: This meta‐analysis finally included 15 trials involving a total of 4505 patients. The eradication rates for short courses of BcQT were lower than those for the 14‐day course (RR 0.96, 95% CI 0.93–0.99). However, the eradication rate for the 10‐day therapy was comparable to that of the 14‐day therapy (RR 0.98, 95% CI 0.95–1.00). Subgroup analyses of antibiotic combinations indicated that tetracycline and metronidazole combinations yielded similar H. pylori eradication rates in the 7‐day versus the 14‐day BcQT (RR 0.93, 95% CI 0.84–1.02). In the potassium‐competitive acid blocker subgroup, the eradication rates remained similar across the 14‐day group and the short‐course treatment groups, whether evaluating the short‐term treatment groups as a whole or the 7‐ and 10‐day subgroups separately. Additionally, the adverse effects and compliance associated with the short course of BcQT were comparable to those of the 14‐day therapy.Conclusion: A 10‐day course of BcQT may represent the optimal treatment duration. Nevertheless, the choice of antibiotic combination should be guided by the regional antibiotic resistance patterns of H. pylori, as combinations with lower resistance rates are more effective.Trial Registration: PROSPERO number: CRD42024547773
- 1 September 2024
- Published by Wiley in Helicobacter
- Vol. 29 (5) , e13144
Optimal Duration of Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis
Background: The eradication of Helicobacter pylori (H. pylori) is crucial due to its rising prevalence and increasing resistance. Bismuth‐containing quadruple therapies (BcQTs) have been proposed as a viable treatment option; however, the optimal duration for it remains contentious. This systematic review and meta‐analysis aimed to compare the clinical efficacy of short‐term BcQT (defined as 7 or 10 days) with a standard 14‐day course.Methods: A systematic search of PubMed, Embase, Web of Science, and the Cochrane Library was conducted for randomized controlled trials published in English until June 20, 2024. Eligibility criteria were applied to identify relevant studies. Summary risk ratios (RRs) and 95% confidence intervals (CIs) were calculated for the included studies regarding eradication rates, adverse effects, and compliance. This systematic review and meta‐analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement and was previously registered in PROSPERO under registration number CRD42024547773.Results: This meta‐analysis finally included 15 trials involving a total of 4505 patients. The eradication rates for short courses of BcQT were lower than those for the 14‐day course (RR 0.96, 95% CI 0.93–0.99). However, the eradication rate for the 10‐day therapy was comparable to that of the 14‐day therapy (RR 0.98, 95% CI 0.95–1.00). Subgroup analyses of antibiotic combinations indicated that tetracycline and metronidazole combinations yielded similar H. pylori eradication rates in the 7‐day versus the 14‐day BcQT (RR 0.93, 95% CI 0.84–1.02). In the potassium‐competitive acid blocker subgroup, the eradication rates remained similar across the 14‐day group and the short‐course treatment groups, whether evaluating the short‐term treatment groups as a whole or the 7‐ and 10‐day subgroups separately. Additionally, the adverse effects and compliance associated with the short course of BcQT were comparable to those of the 14‐day therapy.Conclusion: A 10‐day course of BcQT may represent the optimal treatment duration. Nevertheless, the choice of antibiotic combination should be guided by the regional antibiotic resistance patterns of H. pylori, as combinations with lower resistance rates are more effective.Trial Registration: PROSPERO number: CRD42024547773
- 1 July 2024
- Published by Wiley in Helicobacter
- Vol. 29 (4) , e13115
Artificial Intelligence‐Generated Patient Education Materials for Helicobacter pylori Infection: A Comparative Analysis
Background: Patient education contributes to improve public awareness of Helicobacter pylori . Large language models (LLMs) offer opportunities to revolutionize patient education transformatively. This study aimed to assess the quality of patient educational materials (PEMs) generated by LLMs and compared with physician sourced. Materials and Methods: Unified instruction about composing a PEM about H. pylori at a sixth‐grade reading level in both English and Chinese were given to physician and five LLMs (Bing Copilot, Claude 3 Opus, Gemini Pro, ChatGPT‐4, and ERNIE Bot 4.0). The assessments of the completeness and comprehensibility of the Chinese PEMs were conducted by five gastroenterologists and 50 patients according to three‐point Likert scale. Gastroenterologists were asked to evaluate both English and Chinese PEMs and determine the accuracy and safety. The accuracy was assessed by six‐point Likert scale. The minimum acceptable scores were 4, 2, and 2 for accuracy, completeness, and comprehensibility, respectively. The Flesch–Kincaid and Simple Measure of Gobbledygook scoring systems were employed as readability assessment tools. Results: Accuracy and comprehensibility were acceptable for English PEMs of all sources, while completence was not satisfactory. Physician‐sourced PEM had the highest accuracy mean score of 5.60 and LLM‐generated English PEMs ranged from 4.00 to 5.40. The completeness score was comparable between physician‐sourced PEM and LLM‐generated PEMs in English. Chinese PEMs from LLMs proned to have lower score in accuracy and completeness assessment than English PEMs. The mean score for completeness of five LLM‐generated Chinese PEMs was 1.82–2.70 in patients' perspective, which was higher than gastroenterologists' assessment. Comprehensibility was satisfactory for all PEMs. No PEM met the recommended sixth‐grade reading level. Conclusion: LLMs have potential in assisting patient education. The accuracy and comprehensibility of LLM‐generated PEMs were acceptable, but further optimization on improving completeness and accounting for a variety of linguistic contexts are essential for enhancing the feasibility.
- 1 July 2024
- Published by Wiley in Helicobacter
- Vol. 29 (4) , e13115
Artificial Intelligence‐Generated Patient Education Materials for Helicobacter pylori Infection: A Comparative Analysis
Background: Patient education contributes to improve public awareness of Helicobacter pylori . Large language models (LLMs) offer opportunities to revolutionize patient education transformatively. This study aimed to assess the quality of patient educational materials (PEMs) generated by LLMs and compared with physician sourced. Materials and Methods: Unified instruction about composing a PEM about H. pylori at a sixth‐grade reading level in both English and Chinese were given to physician and five LLMs (Bing Copilot, Claude 3 Opus, Gemini Pro, ChatGPT‐4, and ERNIE Bot 4.0). The assessments of the completeness and comprehensibility of the Chinese PEMs were conducted by five gastroenterologists and 50 patients according to three‐point Likert scale. Gastroenterologists were asked to evaluate both English and Chinese PEMs and determine the accuracy and safety. The accuracy was assessed by six‐point Likert scale. The minimum acceptable scores were 4, 2, and 2 for accuracy, completeness, and comprehensibility, respectively. The Flesch–Kincaid and Simple Measure of Gobbledygook scoring systems were employed as readability assessment tools. Results: Accuracy and comprehensibility were acceptable for English PEMs of all sources, while completence was not satisfactory. Physician‐sourced PEM had the highest accuracy mean score of 5.60 and LLM‐generated English PEMs ranged from 4.00 to 5.40. The completeness score was comparable between physician‐sourced PEM and LLM‐generated PEMs in English. Chinese PEMs from LLMs proned to have lower score in accuracy and completeness assessment than English PEMs. The mean score for completeness of five LLM‐generated Chinese PEMs was 1.82–2.70 in patients' perspective, which was higher than gastroenterologists' assessment. Comprehensibility was satisfactory for all PEMs. No PEM met the recommended sixth‐grade reading level. Conclusion: LLMs have potential in assisting patient education. The accuracy and comprehensibility of LLM‐generated PEMs were acceptable, but further optimization on improving completeness and accounting for a variety of linguistic contexts are essential for enhancing the feasibility.
- 1 May 2024
- Published by Wiley in Helicobacter
- Vol. 29 (3) , e13098
Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial
Background: Potassium‐competitive acid blockers have demonstrated enormous potential in the eradication treatment of Helicobacter pylori infection, with tegoprazan being one of the representatives. The available data on the safety and efficacy of tegoprazan in dual therapy are limited.Materials and Methods: The multicenter, noninferiority, randomized‐controlled trial was conducted from May 2023 to March 2024. Treatment‐naive subjects were randomly assigned (1:1) to enter either the tegoprazan–amoxicillin (TA) group (tegoprazan 50 mg twice daily and amoxicillin 750 mg four times daily) or the esomeprazole–amoxicillin (EA) group (esomeprazole 20 mg and amoxicillin 750 mg all four times daily), with a duration for 14 days. The primary outcome was eradication rate as determined by 13C‐urea breath test, including per‐protocol (PP) analysis and intention‐to‐treat (ITT) analysis. Secondary outcomes were adverse events and compliance.Results: A total of 368 individuals were included in the randomization. The eradication rates in the EA group and the TA group were 84.2% and 85.8%, respectively, according to an ITT analysis (p = 0.77), and 88.5% and 88.2%, respectively, according to PP analysis (p = 1.00). The eradication rates for the TA group were not inferior to those of the EA group in both PP (p = 0.0023) and ITT analyses (p = 0.0009). There were no significant statistical differences in the incidence of adverse events and compliance between the two groups. The multivariate logistic regression analysis revealed that poor compliance increased the risk of eradication failure (p < 0.001).Conclusions: Dual therapy containing tegoprazan is safe and effective to be considered as a clinical first‐line treatment option, but further optimization involving antimicrobial susceptibility testing and adjustments in dosage and frequency is warranted.Trial Registration: ClinicalTrials.gov ID: NCT05870683.
- 1 May 2024
- Published by Wiley in Helicobacter
- Vol. 29 (3) , e13098
Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial
Background: Potassium‐competitive acid blockers have demonstrated enormous potential in the eradication treatment of Helicobacter pylori infection, with tegoprazan being one of the representatives. The available data on the safety and efficacy of tegoprazan in dual therapy are limited.Materials and Methods: The multicenter, noninferiority, randomized‐controlled trial was conducted from May 2023 to March 2024. Treatment‐naive subjects were randomly assigned (1:1) to enter either the tegoprazan–amoxicillin (TA) group (tegoprazan 50 mg twice daily and amoxicillin 750 mg four times daily) or the esomeprazole–amoxicillin (EA) group (esomeprazole 20 mg and amoxicillin 750 mg all four times daily), with a duration for 14 days. The primary outcome was eradication rate as determined by 13C‐urea breath test, including per‐protocol (PP) analysis and intention‐to‐treat (ITT) analysis. Secondary outcomes were adverse events and compliance.Results: A total of 368 individuals were included in the randomization. The eradication rates in the EA group and the TA group were 84.2% and 85.8%, respectively, according to an ITT analysis (p = 0.77), and 88.5% and 88.2%, respectively, according to PP analysis (p = 1.00). The eradication rates for the TA group were not inferior to those of the EA group in both PP (p = 0.0023) and ITT analyses (p = 0.0009). There were no significant statistical differences in the incidence of adverse events and compliance between the two groups. The multivariate logistic regression analysis revealed that poor compliance increased the risk of eradication failure (p < 0.001).Conclusions: Dual therapy containing tegoprazan is safe and effective to be considered as a clinical first‐line treatment option, but further optimization involving antimicrobial susceptibility testing and adjustments in dosage and frequency is warranted.Trial Registration: ClinicalTrials.gov ID: NCT05870683.